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Introduction
Chronic lymphocytic leukemia (CLL) is a neoplastic disorder characterized by mature B-lymphocytes that accumulate due to impaired program cell death (1) . These cells reside in microenvironmental niches such as peripheral blood, bone marrow, and lymph nodes (2) . The gene expression profile differs between compartments, however current treatments do not target the unique biology of this disease (3, 4) . In fact, the standard of care for CLL is a cytotoxic therapy that includes fludarabine plus cyclophosphamide with the monoclonal antibody rituximab (FCR) (5-7). In newly diagnosed patients, FCR results in a 95% overall response rate, with a 70% rate of complete remissions, and about 1/3 of patients have event-free survival for ~10 years (i.e. cure). Yet, the FCR regimen has many limitations. For example, fludarabinebased regimens were not associated with improved outcomes in older (age > 65 yrs) patients, who make up the majority of the CLL population (8). Additionally, patients with markers of poor prognosis, such as 11q del, 17p del, or IgVH unmutated gene or mutated TP53, remain high-risk with shorter progressionfree survival even with FCR combination therapy (9) . Moreover, recent long-term results in first salvage FCR-treated 300 CLL patients emphasize alternative therapeutic strategies. In these individuals, only one-third maintained remission after 12 years, while about 50% developed relapsed/refractory disease, 8% died in remission, and 7% developed second and aggressive malignancies such as acute leukemias or Richter's transformation (10) . These statistics underscore the need for a regimen that targets the biology of CLL disease.
Studies of the B-cell receptor (BCR) axis and its downstream kinases have provided a targeted nonchemotherapy alternative, as this pathway is a primary requisite for development and maintenance of both normal and malignant B-cells (11, 12) . This network is important for B-cell proliferation, differentiation, and survival as well as cell migration and tissue homing (13) . Bruton's tyrosine kinase (BTK) is a pivotal enzyme in the BCR pathway (14) . Ibrutinib (PCI-32765) is a relatively selective and irreversible inhibitor of BTK (14) ; this oral agent binds covalently to cysteine-481, which is located in the active site of this enzyme, thus inhibiting its activity (with an IC 50 = 0.5 nM, and t 1/2 > 24 hours) (15, 16) . Lymph nodes and bone morrow provide tumorigenic protective microenvironments for CLL cells via the BCR network, and consequently, BCR kinase inhibitors disrupt this pathway (11, 17) . In in vitro, ex vivo, and in vivo settings, ibrutinib inhibited the cytoprotective signals from the microenvironment, down-regulated survival and proliferative pathways, and lacked cytotoxicity toward T-cells (12, (18) (19) (20) (21) . Importantly, a Phase I trial (14) , Phase Ib/II trial (22) , and subsequent trial of ibrutinib in elderly patients with CLL (23) demonstrated high tolerability and an overall response rate of >70%, with a 26 month progression-free and overall survival rate of >75% (22) .
Although ibrutinib results in impressive clinical outcomes, it has limitations. First, most responses have been partial remissions, and continuous use of the drug is required. For patients with 17p abnormalities, even ibrutinib as a front-line therapy did not produce any complete remissions (24) . Second, recent genomic profiling studies of CLL patients who acquired resistance to ibrutinib identified resistance mutations in BTK and phospholipase Cγ2 kinase, as well as genetic alterations unrelated to the BCR pathway (25) (26) (27) (28) . Third, while lymph nodes shrink after ibrutinib therapy, the disease is not cleared efficiently from the bone marrow (22) .
To overcome these limitations, we performed a pharmacologic profiling in residual circulating CLL cells after ibrutinib therapy to identify agents that could induce cell death of these lymphocytes. These postibrutinib CLL cells were incubated with phosphatidylinositol-3 kinase (PI3K) inhibitors (idelalisib or IPI-145), a chemotherapeutic agent (bendamustine), additional ibrutinib, BCL-2 antagonist (venetoclax, ABT-199), or BCL-2 and BCL-X L antagonist (ABT-737). The BCL-2 antagonists (especially most effectively induced cell death during ex vivo incubations. In accordance with these results, the in vitro combination of ibrutinib and a BCL-2 antagonist showed additive or more than additive cytotoxicity. Serial samples of CLL cells obtained from patients on clinical trial, before (base line) and after (at 2, 4, 12 and 36 weeks) ibrutinib therapy initiation, showed inhibition of BTK activity, decreased MCL-1 protein, and increased sensitivity to the BCL-2 antagonists. Collectively, among the agents tested, our results identified ABT-199 as an ideal partner to be combined with ibrutinib.
Research. 
Materials and Methods
Drugs and Reagents. Ibrutinib and ABT-199 were respectively purchased from Selleckchem (Houston, TX) and Xcessbio (San Diego, CA), while ABT-737 was provided by Abbott (Park, IL). Goat F(ab′)2 fragments to human IgM was purchased from MP Biomedicals (Santa Ana, CA).
Isolation of Lymphocytes.
All experiments were carried out using freshly isolated cells from peripheral blood of patients with CLL. After isolation, cells were immediately suspended in warm medium; there was no interval freezing. Patients gave written informed consent to participate in this laboratory protocol, which was approved by the institutional review board of MD Anderson Cancer Center. Cells were isolated using Ficoll-Hypaque (Life Technologies, Grand Island, NY) as described (18) . The isolated lymphocytes were resuspended (1 x 10 7 cells/mL) in RPMI-1640 medium supplemented with 10% human AB serum (Cambrex Biosciences, East Rutherford, NJ). The cell number and mean cell volume were determined using a Coulter Channelyzer (Coulter Electronics, Hialeah, FL).
Sample Collection during Clinical Trial.
For ex vivo incubations and for serial sampling, blood samples were obtained from patients enrolled in ibrutinib trials. All patients received 420 mg of ibrutinib per day, and samples were collected before and/or at 2, 4, and 12 weeks after start of ibrutinib treatment.
Collection of blood sample at baseline and at 36 weeks post ibrutinib therapy (used for Supplementary Figure 3 ) was also done at Ohio State University using an IRB approved clinical protocol. were analyzed using stripping and re-probing of the membrane. Primary antibodies to detect total and phosphorylated proteins and their sources are listed (Supplementary Table S1 ).
Gene Expression Assay. RNA was isolated using the RNAeasy kit (Qiagen, Valencia, CA), and relative transcript levels of gene expression were assessed using TaqMan One Step RT-PCR (Applied Biosystems, Foster City, CA). Predesigned primers and probes are listed (Supplementary Table S1 ).
Experiments were done in triplicate, and the results were plotted as fold change compared to control.
Reverse-Phase Protein Array (RPPA).
Protein lysates from CLL cells from patients on clinical trials were arrayed on nitrocellulose coated slides and were probed with antibodies. The signal obtained was amplified using a Dako Cytomation-catalyzed system (Dako, Carpinteria, CA). Relative protein levels were determined by interpolation of each dilution curve, and all data were normalized for protein loading.
Linear mixed-effect modeling was used to assess the differences in protein expression. This model includes the fixed effect of time point (2 levels: pre-vs. post-treatment) and the random effect of patient.
To account for multiple testing, we estimated the false discovery rates of the F-tests of the time point effect using the Benjamini-Hochberg method (29) . 
Statistical Analysis and Determination of Drug Interactions
Statistical tests were done using GraphPad Prism (GraphPad Software, San Diego, CA). For calculation of ibrutinib and second drug interaction, we used the fractional product method described by JL Webb.
The fractional product was used to determine whether the effect on cell viability and apoptosis induced by the combinations was additive/synergistic/antagonistic. This method is appropriate when nonexclusive drugs (agents with independent mechanisms of action) are combined. 
Results

Ex vivo studies of post-ibrutinib residual circulating CLL cells
Blood from patient #595, who had been treated with ibrutinib for 4 weeks, was obtained and lymphocytes were isolated and incubated ex vivo for 24 hours with 6 drugs at the indicated concentrations and cell death was measured. The level of endogenous cell death was subtracted from each sample. ABT-737 and ABT-199 (5 and 10 nM) resulted in >60% apoptosis, while a low cytotoxic effect was observed for the other agents (Fig. 1A) . In order to confirm this pattern of cytotoxicity, we obtained blood samples from 10 additional patients who had received ibrutinib for 4 weeks and incubated their lymphocytes in the same manner (Fig. 1B) . Overall, ABT-199 was the most potent cytotoxic agent (median cell death: 61%), followed by ABT-737 (median cell death: 33%) ( Fig. 1Band Supplementary Table S2), regardless of the patients' cytogenetics, disease stage, and previous treatment (Supplementary Table S3 ). Significant cytotoxicity was determined for ABT-199 when it was compared to the rest of agents including ABT-737 (Fig. 1B, p value < 0.004). Still, excluding ABT-199, when compared to the other agents, ABT-737 also induced significant cell death. Altogether, these data suggest that BCL-2 inhibition is effective in ibrutinib-treated lymphocytes.
To determine if the ABTs' cytotoxicity could be replicated at earlier and later time points, we isolated lymphocytes from peripheral blood collected at shorter and longer times after patients began ibrutinib treatment. The rates of ABT-737-mediated cell death were a median 47%, 33%, and 38% in samples collected at 2 (n=2), 4 (n= 9), and 12 weeks (n=7) post-ibrutinib, respectively ( 
In vitro studies in lymphocytes from ibrutinib-naïve CLL patients
To determine if the ex vivo results could be recapitulated in vitro, we studied lymphocytes from ibrutinibnaïve CLL patients. To determine optimal concentrations to use, we calculated the IC 50 values of ibrutinib and the BCL-2 antagonists alone and in combination; the IC 50 value for ibrutinib was ~10 µM ( Fig. 2A) , while those for ABT-737 ( To define the in vitro cytotoxic impact of the combination strategy, we incubated CLL cells with vehicle (DMSO), ibrutinib, an ABT, and their combination for 24 hours (Fig. 2H-I ). To investigate the role of ibrutinib when the BCR pathway is active, we conducted a parallel experiment of the same 4 treatments in cells stimulated with 10 μg/mL anti-IgM. This stimulation always resulted in less cell death. Still, both combination treatments (ibrutinib plus ABT-737 or ABT-199) were more cytotoxic than the single agents ( Fig. 2H-I ). Similar studies were performed in additional primary CLL samples ( Table 1) death, which was higher than expected (23-53%). Similar results were observed in the stimulation treatments (8-60%), with rates of cell death higher than expected (3-50%). These data suggest that the combination of ibrutinib and an ABT is more cytotoxic against CLL cells than any of the agents alone, regardless of whether BCR is active and independent of the patients' cytogenetics (Supplementary Table   S3 ); the combined level of cytotoxicity was either additive or synergistic. 
Ex vivo studies of pre-and post-ibrutinib residual circulating CLL cells
To establish if lymphocytes differed in drug sensitivity before and after ibrutinib therapy, we collected a sample (from patient #775) at weeks 0 (pre-ibrutinib), 4, and 12 (post-ibrutinib) (Fig. 3A) . ABT-737 and especially ABT-199 resulted in increased cell death compared to the other agents regardless of ibrutinib treatment time. To confirm these results, we collected 5 additional patient samples for the same weeks and tested them under similar conditions with all 6 drugs as well as with vehicle (DMSO) control.
Endogenous cell death (in vehicle control sample) was higher in pre-ibrutinib lymphocyte sample (median endogenous cell death, 29%, range 5-57%) than in sample 4-weeks post-ibrutinib (median 10%, range 10-36%) and sample 12-week post-ibrutinib(median 12%, range: 4-13%) (Fig. 3B) . The level of endogenous cell death was not associated with the increase or decrease in lymphocyte count after ibrutinib therapy (Fig. 3C) . Except in 1 patient (#327) treated with bendamustine, all drugs elicited <40% cytotoxicity (Fig. 3D) . ABT-737-and ABT-199-induced cytotoxicity was plotted for the same 6 CLL samples at weeks 0, 4, and 12 (Fig. 3E) . ABT-737-mediated median cell death was similar in pre-ibrutinib and post-ibrutinib CLL samples (Supplementary Table S5 ). ABT-199 treatment yielded higher levels of cell death overall, but the values were similar in pre-ibrutinib samples (median, 53%) and samples obtained at 4 weeks (57%) and 12 weeks (59%) after the start of ibrutinib therapy (Supplementary Table   S5 ). Samples obtained at 36 weeks and treated at a separate site (Ohio State University) also showed similar extent of sensitivity to ABT-199 (median 58% apoptosis; Supplementary Fig. S3 ). These data suggest that lymphocytes prior to ibrutinib or residual CLL cells post-ibrutinib are similarly sensitive to ABT-induced cytotoxicity. Furthermore, both the in vitro and ex vivo studies demonstrated that ABT-199 is more potent than ABT-737.
Immunoblots were performed in lymphocytes obtained from patients on ibrutinib treatment. Ibrutinib administration resulted in inhibition of BTK activity in primary CLL cells, as shown by the decrease in autophosphorylation at p-BTK-Y 223 ( Fig. 4A-B) . To evaluate the impact of this inhibition on changes in the levels of BCL-2 family proteins, we performed reverse phase protein array (RPPA) in the same freshly obtained CLL cells isolated from peripheral blood of patients receiving ibrutinib. There was a consistent and significant decline in MCL-1 protein levels (Fig. 5A, p=0 .0042), with some changes in BCL-X L and BCL-2 ( Fig. 5B-C , respectively). Immunoblot assays followed by quantitation validated the RPPA results. For example, levels of antiapoptotic proteins MCL-1 and BCL-X L (Fig. 5D ) declined significantly after 4 and 12 weeks of ibrutinib therapy (Fig. 5E-F, respectively) . In contrast, BCL-2 ( Fig.   5D and 5G) levels showed no consistent decrease or increase after ibrutinib therapy on the 6 analyzed CLL samples. This was not related to cytogenetics, prognostic factor, or disease state. Levels of Bim, total and p-ERK1/2-T 202 /Y 204 , and total and p-AKT-S 473 ( Supplementary Fig. S4 ) remained unchanged or 
showed heterogeneity in response to ibrutinib therapy (quantitation of phosphorylated versus total AKT and ERK proteins are provided below the immunoblot).
RT-PCR analyses for the antiapoptotic proteins MCL-1, BCL-X L , and BCL-2 were performed to determine if the decrease observed at the protein level was due to diminished mRNA levels. Only 4 of 6 samples showed a decline in MCL-1 and BCL-X L transcript levels; BCL-2 results were heterogeneous (Fig. 5H-J, respectively) .
In vitro studies in lymphocytes from TCL1 mouse model
To determine if the human CLL cell studies could be recapitulated in lymphocytes derived from a CLL mouse model, cells from the TCL1 mouse were isolated and incubated with ABT-199 (0.5 and 1nM) and ibrutinib (10 µM) for 24 hours. These data resulted in an additive or more than additive cell death as assessed by Annexin V/PI staining ( Supplementary Fig. S5 ), which is consistent with human CLL cell studies (Table 1) .
Discussion
Ibrutinib has revolutionized how we treat CLL; it targets the very pathway that is involved in production and maintenance of B-lymphocytes. Ibrutinib covalently binds and inhibits BTK, which is critical in the BCR pathway. Recent investigations have identified that signaling proteins in the BCR axis not only play a pivotal role in the development of normal and malignant B-cells but also become mutated or modified in CLL cells from patients whose disease is becoming resistant to ibrutinib (25) (26) (27) (28) . Hence, targeting additional elements in the BCR pathway could result in increased cytotoxicity. Idelalisib (GS1101) targets the p110 delta isoform of PI3K, while IPI-145 targets both delta and gamma isoforms (31, 32) .
These PI3K subunits are expressed at high levels primarily in lymphocytes, providing selectivity with these inhibitors. Because these kinases dominate the BCR pathway, they were primary molecules for our testing. Consistent with the data with idelalisib and IPI-145, additional ibrutinib also did not provide increased cytotoxic benefit (Fig. 1B and 3D ). While these inhibitors may provide an advantage in the clinic by mobilizing CLL cells from the lymph nodes, our primary goal was to induce cell death in cells that are either mobilized or residual after ibrutinib. Furthermore, the kinase inhibitors may be effective for ibrutinib-resistant CLL clone (33) . Bendamustine, an approved and well-tolerated alkylating agent for CLL, also was not a stimulator for cell death (34) . In contrast to these above tested agents, inhibition of BCL-2 consistently resulted in induction of cell death. Furthermore, between the two BH3-mimetics, ABT-199 unfailingly produced the higher percentage of cell death.
For the current investigation, we selected 6 drugs based on their current use for treatment of CLL and mechanistic rationale to combine with ibrutinib. Earlier preliminary investigations in ibrutinib-treated CLL patient samples identified transcription inhibitor, dinaciclib, that targets cyclin-dependent kinase (CDK) inhibitor as a potent cell death inducer in these lymphocytes (35) . In contrast, similar to present investigation, kinase inhibitors that impact components of BCR pathway did not induce apoptosis.
Recent investigations using similar model system suggested carfilzomib, an endoplasmic reticulum (ER) stress agent, as a potential partner with ibrutinib (36) . The positive interaction between these drugs was Fig. 1C and 1D ), and 36 ( Supplementary Fig. S3 ) showed similar cell death with ABT-199.
Because, ABT-199-mediated cytotoxicity was similar in pre-and post-ibrutinib samples, these data suggest that most of the cell death response is generated by . Similar to CLL model system, major efforts have been utilized in other B-cell malignancies where ibrutinib and BCL-2 antagonists have shown promising activity in B-cell diseases such as mantle cell lymphoma (37),Waldenstrom's macroglobulinaemia (38) , and diffuse-large B-cell lymphoma (39). Ibrutinib's primary action on cell proliferation is in concert with co-operation with transcription inhibitor dinaciclib, ER stressor carfilzomib, and BCL-2 antagonist, ABT-199. These reports direct us to recognizing best small molecule combination drug partner with ibrutinib. However, combination strategies that pair ibrutinib with rituximab, GA101, or ofatumumab warrant preclinical testing especially because efficacy with antibodies to treat CLL has been shown in the clinic and these agents are FDA approved (40) .
While detailed mechanistic studies were not performed, CLL biology, characteristics of these agents, and the results obtained with these combinations provide clues to explain these cell death differences. Among the 6 BCL-2 family survival proteins, BCL-2, BCL-X L , and MCL-1 are the most abundant in CLL cells (41) . In addition, among these 3 proteins, BCL-2 and BCL-X L are present at levels 4-12 times higher than MCL-1 (42) . While ABT-737 targets and binds with high affinity (Ki ≤ 1 nM) to the hydrophobic BH3-binding groove of BCL-X L , BCL-2, and BCL-w (43); ABT-199 targets only BCL-2 with much higher potency (Ki ≤ 0.01 nM) (44) . Prolonged and potent perturbation of either BCL-2 or BCL-X L should result in apoptosis, as the overall stoichiometry of these molecules is a determinant of CLL cell survival or death (37) . Ibrutinib and ABT-737 cooperated well in DLBCL (39) . Finally, our data suggest that ibrutinib therapy constantly causes an intracellular MCL-1 decrease (Fig. 5A, 5D , and 5E), which may further augment ABT-199-induced apoptosis. While detailed time kinetics were not captured in our investigations, at 4 and 12 weeks after ibrutinib initiation, CLL cells consistently showed a decline in MCL-1 protein levels in RPPA and immunoblot assays (Fig. 5A, 5D, 5E ). This result however was not observed during in vitro incubations, which can be attributed to limited incubation time (24 hour for in vitro assays versus minimum 2 weeks for in vivo studies) with ibrutinib ( Supplementary Fig. S1 ). MCL-1 protein decrease or induction of pro-apoptotic protein Noxa by dinaciclib and carfilzomib, respectively may be the primary mechanisms for increased cell death.
The decline in MCL-1 protein level was partly (4 of 6 samples) associated with a decrease in MCL-1 transcript level in post-ibrutinib samples (Fig. 5H) . The BCR pathway, including the PI3K/AKT axis, has been shown to impact transcriptional, translational, and post-translational modifications of MCL-1, resulting in increased transcription, over-expression of protein and longer maintenance of protein (45) (46) (47) .
Both during in vitro incubations (Fig. 2J ) and especially during clinical trials (Fig. 4A-B) , ibrutinib reliably inhibited BTK activity (measured as p-BTK). Our results are in accordance with a previous study showing a decrease in BTK phosphorylation in circulating CLL cells during therapy and consistent with the observation that at a dose of 420 mg/day, ibrutinib completely occupied the BTK binding pocket (14, 35) . Hence, it can be presumed that the BTK pathway would be abrogated in the leukemia cells of these CLL patients, impacting transcriptional and translational modifications of MCL-1 and other proteins.
Inhibition of BTK pathway resulted in unexpected increase in circulating leukemia cells that were due to mobilization of lymphocytes from lymph nodes (22) . It has been established that at the molecular level, there are differences in malignant CLL lymphocytes from peripheral blood, bone marrow, and lymph nodes. An increased BCR signature, proliferation markers, and NF-kB activity was identified in gene expression array analyses in cells from lymph node compared to those from marrow or blood (4). increased expression of BCL-2 protein measured by RPPA assay (Fig. 5C ) and validated by immunoblot assay (Fig. 5G) .
To mimic these ex vivo studies, we performed in vitro combination cytotoxicity assays by combining BH3 mimetics with ibrutinib. To model BCR stimulation, parallel cultures were anti-IgM stimulated.
Compared to expected cytotoxicity, calculated based on single agent response in each sample, the observed cytotoxicity was significantly higher. The extent of this difference was strongest when cells were stimulated for the BCR pathway (p values = 0.0004 and 0.0002 with ABT-737 and ABT-199, respectively, Table 1 ). Collectively these in vitro and ex vivo results demonstrate the utility and benefit of combining ABT-199 with ibrutinib in the clinic. Translation of these preclinical results to clinic should be feasible. The clinically-decided dose of ibrutinib for CLL (420 mg) is well-tolerated and is actually below the maximum tolerated dose. At this dose, the peak plasma concentration of free drug is around 80 ng/ml; equivalent to 0.2 µM. While in the present work, ibrutinib is used at 10 µM, due to serum/plasma protein binding, the free drug is less than 3% (i.e. 0.3 µM) which is similar to what is acquired during therapy (22) . Similarly, the concentration of ABT-199 in our experiments was 1-10 nM, which is easily achievable in the clinic (44, 49) .
While these ex vivo investigations of CLL cells during ibrutinib therapy provide a novel and unique cell population to identify small molecule drugs that collaborate well with ibrutinib, there are limitations of this system. First, we only used annexin/PI positivity to identify partner agent for ibrutinib. It is highly likely that agents which may not induce profound CLL lymphocyte death will be missed during such interrogations. Second, CLL cells pre and post ibrutinib are non-proliferative during ex vivo or in vitro culturing. Needless to say that in such a model system, agents that are tackling cell proliferation would not be identified. Third, pathways such as PI3K, AKT, mTOR, and NF-kB that may be critical in CLL biology were not tested during these incubations. Investigations on impact of these networks may provide other molecules to be added to ibrutinib. Finally, animal model system that can recapitulate CLL cells in different niches and microenvironment (blood, bone-marrow, and lymph node) may provide selective targeted agents to be coupled with ibrutinib.
Even with these shortcomings, our data and prior investigations provide clear rationale that (and ABT-737) is beneficial to ibrutinib therapy. First, among the tested agents, addition of was most conducive in inducing apoptosis. Second, residual or lymphocytosed cells were sensitive to ABT-199-mediated cytotoxicity. Third, compared to base-line (prior to ibrutinib) CLL cells, postibrutinib mobilized CLL cells were relatively resistant to cell death (data not shown). However, they were equally sensitive to (Supplementary Table S5 ). Fourth, at the systemic level, CLL cells reside in 3 different niches in the human body: lymph nodes, bone marrow, and peripheral blood.
Ibrutinib preferentially targets the lymph node reservoir, while ABT-199 addresses CLL cells residing in blood and marrow. Early preliminary data (44) and data from a subsequent Phase I study of ABT-199 in patients with high-risk relapsed or refractory CLL (49) reported an overall response rate of 84%, with a complete remission rate of 23%. Notably, ABT-199 resulted in the clearance of leukemia cells from the blood and marrow. In fact, no or low minimum residual disease was observed in 8 patients treated (49) .
Consequently, these 2 drugs would be beneficial in removing malignant cells from all three compartments.
Our data also suggest that ibrutinib may add benefit to ABT-737 or ABT-199. First, when 2 different doses of ibrutinib were added to ABT-737, the IC 50 of ABT-737 changed from 6 nM to 2 nM to 1 nM (Fig. 2B, 2D and 2F ). Such reduction in IC 50 demonstrates the advantage of adding ibrutinib and it also indicates that in the clinic we can do a dose reduction for ABT-263 which will alleviate drug-induced thromobocytopenia which was problematic for its use. Second, when two different doses of ibrutinib were combined with ABT-199, the IC 50 of ABT-199 was reduced from 2 nM to 1 nM to 0.5 nM (Fig. 2C,   2F and 2G). Hence, in clinic, ibrutinib may be combined with lowest dose of ABT-199 as suggested in the current clinical trial in high-risk patients with relapsed/refractory CLL (49) . Third, data presented in (Fig. 5A, 5D , 5E) provides another advantage to ABT-737 and ABT-199 as these BCL-2 antagonists do not target MCL-1 and this has been shown to be one of the mechanisms for resistance to ABT-263 (50) . At the cellular and molecular level, our data suggest that by combining these two agents (ibrutinib and ABT-199 or ABT-737) we will target all 3 BCL-2 survival proteins, MCL-1, BCL-X L , and BCL-2. CLL malignant cells have been shown to be addicted to these proteins for their maintenance and survival; for example, an ABT-199 resistant cell line was sensitized to ABT-199 by BCR nexus (such as PI3K, AKT, and mTOR) inhibitors (51) . Hence, we postulate that the combination approach described in this study has the potential to eradicate CLL cells and a clinical trial combining these 2 agents is needed to validate this combination. BTK were from the same gel. Since the antibodies were from the same species, the membrane was stripped and re-probed. We use a fluorescence based imaging system, LiCor Odyssey system to analyze our immunoblots. B, Quantitation was performed for each band, and results plotted as change compared to control (week 0) for each post-ibrutinib sample (weeks 2, 4, or 12) and plotted for p-BTK. 
